Teva Pharmaceuticals presented real-world data on September 18, 2026, showing its schizophrenia treatment UZEDY reduces emergency department visits and healthcare costs compared to other long-acting injectables.

The findings, shared at Psych Congress in New Orleans, demonstrate that once-monthly UZEDY improves treatment continuity for adults with schizophrenia and bipolar I disorder (BD-I). The data highlights significant clinical and economic advantages in real-world settings.

Schizophrenia Outcomes

In a matched cohort of 1,166 patients, fewer individuals receiving UZEDY visited the emergency department compared to those on paliperidone palmitate once-monthly (PP1m). The rates were 22.0% for UZEDY versus 27.8% for PP1m.

UZEDY patients experienced a 40% lower all-cause ED visit rate. Inpatient hospitalization proportions were also numerically lower at 11.1% versus 14.8% for PP1m.

Estimated mean monthly direct healthcare costs were significantly lower for UZEDY at $4,688.10 compared to $5,724.80 for PP1m. This delivered an adjusted mean monthly savings of $1,036.70 per patient.

Adherence and Persistence

Matched cohorts compared UZEDY against risperidone microspheres every-2-weeks, aripiprazole once-monthly, and haloperidol decanoate once-monthly. The greatest differences appeared against risperidone microspheres.

UZEDY patients achieved 3.6x higher odds of adherence (OR: 3.6) and an 80% lower likelihood of discontinuation (OR: 0.2). These patients also recorded lower rates of ED visits and hospitalizations. Outcomes versus aripiprazole once-monthly were generally comparable, while ED visit rates were lower versus haloperidol decanoate once-monthly.

Bipolar I Disorder Data

A retrospective chart review of 358 matched patients evaluated outcomes after switching from oral antipsychotics. Patients who switched to UZEDY experienced significantly less treatment failure (47% vs 63%) compared to those switched to another oral antipsychotic.

Patients receiving UZEDY were more likely to stay on treatment longer without experiencing BD-I or mania-related hospitalizations, ED visits, or discontinuation due to inadequate effectiveness.

What the Numbers Show

The cost savings are driven primarily by reduced acute care utilization rather than drug pricing alone. With direct monthly costs dropping from $5,724.80 to $4,688.10, the $1,036.70 saving represents approximately 18% of the total baseline cost burden for the comparator group. This divergence aligns with the 40% reduction in ED visit rates, suggesting that preventing psychiatric emergencies is the primary economic lever for UZEDY's value proposition in schizophrenia management.

Teva Pharmaceutical Industries Ltd (NYSE and TASE: TEVA) presented new post hoc data from the pivotal Phase 3 SOLARIS trial for its investigational once-monthly subcutaneous long-acting injectable (LAI) olanzapine, TEV-749. The findings were shared at Psych Congress in New Orleans on September 15, 2026, ahead of an anticipated FDA approval decision in Q4 2026.

The data focuses on the efficacy, safety, and durability of TEV-749 for treating schizophrenia in adults. Teva highlighted that more than half of participants achieved stabilization, with low relapse rates among those stabilized. Additionally, analyses support direct switching strategies from daily oral or short-acting intramuscular olanzapine to the monthly subcutaneous injection.

Stabilization and Remission Rates

In a post hoc analysis of the open-label safety stage of the SOLARIS trial, significant proportions of participants met key clinical endpoints. Among 411 participants receiving TEV-749, 231 (56%) achieved stabilization. The stabilization rates across dose groups were 61% for the 318-mg group, 54% for the 425-mg group, and 54% for the 531-mg group.

Among the 231 participants who achieved stabilization, only 10 (4%) experienced relapse. Relapse rates by dose group were 6% for the 318-mg group, 1% for the 425-mg group, and 5% for the 531-mg group. Furthermore, among 183 participants treated with TEV-749 for six or more months, 39 (21%) met criteria for remission. Remission rates were 26% for the 318-mg group, 13% for the 425-mg group, and 26% for the 531-mg group.

Switching Strategies and Safety

Separate analyses simulated potential switching scenarios for patients currently on other olanzapine formulations. Initiating TEV-749 one day after the last dose of oral or short-acting intramuscular olanzapine resulted in predictable olanzapine exposures within established therapeutic ranges. These findings provide clinical insights for healthcare providers managing transitions to the once-monthly injectable.

Metabolic outcome analyses indicated that the metabolic profile of TEV-749 was consistent with daily oral olanzapine formulations. No clear dose-dependent pattern was observed in these metabolic outcomes, supporting the broader safety and tolerability findings from the SOLARIS program.

What the Numbers Show

The divergence between stabilization and remission rates suggests that while a majority of patients achieve symptom control, sustained remission remains a higher threshold. With 56% of participants achieving stabilization but only 21% of those treated for six months or longer meeting remission criteria, the data indicates that long-term maintenance is distinct from initial acute response management.

Regulatory Outlook

TEV-749 utilizes SteadyTeq technology, a proprietary copolymer from Medincell that provides controlled, sustained release of olanzapine. The drug is not yet approved by any regulatory authority. A PDUFA decision from the US Food and Drug Administration is expected in Q4 2026. In Europe, the European Medicines Agency accepted the Marketing Authorization Application for TEV-749 in May 2026.